SCHEDULE 13G/A: Barclays PLC Files Amended Schedule 13G for Surmodics Inc. Common Stock, Confirming Passive Stake

Barclays PLC has filed an amended Schedule 13G, indicating its beneficial ownership of Surmodics Inc. common stock remains at 5% or less, held in the ordinary course of business.

Summary

• Barclays PLC filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in SURMODICS INC.
• The filing pertains to COMMON-STOCK securities of SURMODICS INC (CUSIP: 868873100).
• Barclays PLC, with its principal business office at 1 Churchill Place, London E14 5HP, is the reporting person.
• The filing confirms that Barclays PLC owns 5 percent or less of the class of securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of SURMODICS INC.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing disclosing beneficial ownership, containing no positive or negative performance indicators or forward-looking statements that would influence sentiment.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a routine disclosure by a major financial institution, Barclays PLC, regarding its passive investment in Surmodics Inc. Such filings are common for institutional investors holding less than 5% of a company's shares without intent to influence control, reflecting standard portfolio management activities rather than specific industry-wide strategic shifts.

Stakeholder Impact

• Primarily provides transparency to shareholders regarding institutional ownership.

Key Dates

Keywords

Barclays PLC, SURMODICS INC, Schedule 13G, Common Stock, Beneficial Ownership, SEC Filing, Institutional Investment, Financial Disclosure